FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3022589515> ?p ?o ?g. }

• W3022589515 endingPage "VII" @default.
• W3022589515 startingPage "I" @default.
• W3022589515 abstract "Nilotinib is a BCR-ABL1 tyrosine kinase inhibitor approved for the treatment of patients with chronic myeloid leukemia in chronic phase (CML-CP). This study was the first prospective evaluation of the efficacy and safety of nilotinib in Turkish patients with newly diagnosed CML-CP. The primary endpoint of the study was the rate of major molecular response (MMR; BCR-ABL1 ≤ 0.1% on the International Scale [BCR-ABL1IS]) by 12 months.Patients with newly diagnosed CML-CP were treated with nilotinib 300 mg twice daily. This analysis was based on the first 12 months of follow-up in a 24-month study. This study is registered with ClinicalTrials.gov (NCT01274351).Of 112 patients enrolled, 66.1% (80% CI, 59.7-72.0%) achieved MMR and 22.3% achieved a deep molecular response of MR4.5 (BCR-ABL1IS ≤0.0032%) by 12 months. During the first year of treatment, one patient progressed to blast crisis and two patients died. Safety results were consistent with previous studies. Most adverse events (AEs) were grade 1/2. Most frequently reported nonhematologic AEs of any grade were elevations in bilirubin, alanine aminotransferase, and triglycerides.These results support the use of nilotinib 300 mg twice daily as a standard-of-care treatment option for patients with newly diagnosed CML-CP with low and intermediate risk." @default.
• W3022589515 created "2020-05-13" @default.
• W3022589515 creator A5008989139 @default.
• W3022589515 creator A5011331320 @default.
• W3022589515 creator A5011506725 @default.
• W3022589515 creator A5018463325 @default.
• W3022589515 creator A5018508176 @default.
• W3022589515 creator A5023263554 @default.
• W3022589515 creator A5031256616 @default.
• W3022589515 creator A5033676611 @default.
• W3022589515 creator A5034455441 @default.
• W3022589515 creator A5035484545 @default.
• W3022589515 creator A5043620809 @default.
• W3022589515 creator A5057286844 @default.
• W3022589515 creator A5074020107 @default.
• W3022589515 creator A5076735212 @default.
• W3022589515 creator A5082089864 @default.
• W3022589515 creator A5083473418 @default.
• W3022589515 creator A5085498128 @default.
• W3022589515 creator A5090217849 @default.
• W3022589515 date "2018-02-27" @default.
• W3022589515 modified "2023-10-17" @default.
• W3022589515 title "RETRACTED ARTICLE: Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase" @default.
• W3022589515 doi "https://doi.org/10.1080/10245332.2018.1444919" @default.
• W3022589515 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29486663" @default.
• W3022589515 hasPublicationYear "2018" @default.
• W3022589515 type Work @default.
• W3022589515 sameAs 3022589515 @default.
• W3022589515 citedByCount "0" @default.
• W3022589515 crossrefType "journal-article" @default.
• W3022589515 hasAuthorship W3022589515A5008989139 @default.
• W3022589515 hasAuthorship W3022589515A5011331320 @default.
• W3022589515 hasAuthorship W3022589515A5011506725 @default.
• W3022589515 hasAuthorship W3022589515A5018463325 @default.
• W3022589515 hasAuthorship W3022589515A5018508176 @default.
• W3022589515 hasAuthorship W3022589515A5023263554 @default.
• W3022589515 hasAuthorship W3022589515A5031256616 @default.
• W3022589515 hasAuthorship W3022589515A5033676611 @default.
• W3022589515 hasAuthorship W3022589515A5034455441 @default.
• W3022589515 hasAuthorship W3022589515A5035484545 @default.
• W3022589515 hasAuthorship W3022589515A5043620809 @default.
• W3022589515 hasAuthorship W3022589515A5057286844 @default.
• W3022589515 hasAuthorship W3022589515A5074020107 @default.
• W3022589515 hasAuthorship W3022589515A5076735212 @default.
• W3022589515 hasAuthorship W3022589515A5082089864 @default.
• W3022589515 hasAuthorship W3022589515A5083473418 @default.
• W3022589515 hasAuthorship W3022589515A5085498128 @default.
• W3022589515 hasAuthorship W3022589515A5090217849 @default.
• W3022589515 hasBestOaLocation W30225895151 @default.
• W3022589515 hasConcept C104317684 @default.
• W3022589515 hasConcept C121608353 @default.
• W3022589515 hasConcept C126322002 @default.
• W3022589515 hasConcept C138626823 @default.
• W3022589515 hasConcept C185592680 @default.
• W3022589515 hasConcept C197934379 @default.
• W3022589515 hasConcept C203092338 @default.
• W3022589515 hasConcept C2777413986 @default.
• W3022589515 hasConcept C2777583451 @default.
• W3022589515 hasConcept C2778729363 @default.
• W3022589515 hasConcept C2778820342 @default.
• W3022589515 hasConcept C2778904597 @default.
• W3022589515 hasConcept C535046627 @default.
• W3022589515 hasConcept C55493867 @default.
• W3022589515 hasConcept C71924100 @default.
• W3022589515 hasConcept C90924648 @default.
• W3022589515 hasConceptScore W3022589515C104317684 @default.
• W3022589515 hasConceptScore W3022589515C121608353 @default.
• W3022589515 hasConceptScore W3022589515C126322002 @default.
• W3022589515 hasConceptScore W3022589515C138626823 @default.
• W3022589515 hasConceptScore W3022589515C185592680 @default.
• W3022589515 hasConceptScore W3022589515C197934379 @default.
• W3022589515 hasConceptScore W3022589515C203092338 @default.
• W3022589515 hasConceptScore W3022589515C2777413986 @default.
• W3022589515 hasConceptScore W3022589515C2777583451 @default.
• W3022589515 hasConceptScore W3022589515C2778729363 @default.
• W3022589515 hasConceptScore W3022589515C2778820342 @default.
• W3022589515 hasConceptScore W3022589515C2778904597 @default.
• W3022589515 hasConceptScore W3022589515C535046627 @default.
• W3022589515 hasConceptScore W3022589515C55493867 @default.
• W3022589515 hasConceptScore W3022589515C71924100 @default.
• W3022589515 hasConceptScore W3022589515C90924648 @default.
• W3022589515 hasFunder F4320310388 @default.
• W3022589515 hasIssue "9" @default.
• W3022589515 hasLocation W30225895151 @default.
• W3022589515 hasLocation W30225895152 @default.
• W3022589515 hasOpenAccess W3022589515 @default.
• W3022589515 hasPrimaryLocation W30225895151 @default.
• W3022589515 hasRelatedWork W1974135663 @default.
• W3022589515 hasRelatedWork W2001546361 @default.
• W3022589515 hasRelatedWork W2014173159 @default.
• W3022589515 hasRelatedWork W2032331743 @default.
• W3022589515 hasRelatedWork W2062840910 @default.
• W3022589515 hasRelatedWork W2560510265 @default.
• W3022589515 hasRelatedWork W2617994288 @default.
• W3022589515 hasRelatedWork W2741027314 @default.
• W3022589515 hasRelatedWork W2995921845 @default.
• W3022589515 hasRelatedWork W3093354443 @default.
• W3022589515 hasVolume "23" @default.

• next